Date: 2017-01-05
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Valneva (France- Austria) MSD Animal Health, a Merck&Co company (USA - NJ)
Therapeutic area: Veterinary medicine
Type agreement: licensing
Action mechanism: EB66® cell line is a highly efficient platform for vaccine production. It is derived from duck embryonic stem cells and today represents a compelling alternative to the use of chicken eggs for large scale manufacturing of human and veterinary vaccines. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology. The first human vaccine using EB66® technology received marketing approval in 2014 and the first veterinary vaccine in 2012.
Disease:
Details: * On January 5, 2017, Valneva announced that it has signed a research license agreement with MSD Animal Health. The agreement grants MSD Animal Health the rights to research new vaccine candidates using Valneva’s EB66® technology. MSD Animal Health and Valneva had already signed a commercial license agreement in 2009 allowing MSD Animal health to develop and commercializeEB66®-based vaccines for an undisclosed indication.
Financial terms: Financial terms of the agreements were not disclosed.
Latest news:
